|
||||
|
Dear Reader, By far, the most significant incremental development in recent weeks was the expansion of InSightec’s European CE mark for uterine fibroids. The mark now includes adenomyosis, a benign yet painful gynecologic condition, and gives a new patient population access to the benefits of MR-guided focused ultrasound therapy. Other important, incremental achievements spotlighted in this month’s newsletter are:
We congratulate everyone who made these developments possible. The field of MR-guided focused ultrasound is advancing because of the steady progress being made on many fronts. Ultimately, the persistence and commitment that underlies incremental achievements will save lives and alleviate suffering for millions of people worldwide. |
Don’t miss out: discounted “Early Bird” registration ends July 31 for 2nd International Symposium on MR-guided Focused Ultrasound |
|||
|
|||
EU approves new indication, adenomyosis, for MR-guided focused ultrasound |
|||
|
|||
Sponsor list announced for 2010 MR-guided Focused Ultrasound Symposium |
|||||
|
|||||
Capitol Hill event features MR-guided focused ultrasound technology | |||
|
|||
UVA Focused Ultrasound Center of Excellence launches clinical trials program | |||
|
|||
Utah researcher developing FUS treatments for breast and liver cancer | |||
|
|||
Foundation participates in FDA satellite symposium on targeted drug delivery | |||
|
|||
Fibroid Relief plans July 31 Coffee and Conversation event in London | |||
|
|||
Leading experts join Foundation’s FUS-TDD Core Stakeholder’s Group | |||
|
|||
ISTU reports its 2010 Symposium was a “great success” | |||
|
|||